

Press release
05 December 2022



Spirea welcomes Dr Ludovic Juen to the team as the company further strengthens its drug discovery capabilities

Cambridge, UK, 05 December 2022: Spirea Limited, a biopharmaceutical company developing a new generation of antibody drug conjugate (ADC) cancer therapeutics, is delighted to announce the appointment of Dr Ludovic Juen as a full-time senior scientist in drug discovery.

Dr Juen holds a PhD in Chemistry from the University of Tours in France where he researched the synthesis and pharmacological evaluation of STAT5 inhibitors in chronic myeloid leukaemia. Since completing his PhD, Ludovic has accumulated significant experience in the discovery and development of ADCs including working on innovative bioconjugation and linker-payload technologies and the progression of therapeutic programmes through to preclinical proof-of-concept.

“We are thrilled to welcome Ludovic to the company and are very much looking forward to working with him, and benefitting from his experience, as we advance our pipeline of innovative cancer therapeutics” said Dr Myriam Ouberai, Chief Executive Officer of Spirea.

For further information about Spirea, please visit: www.spirea.co.uk

ENDS

About Spirea www.spirea.co.uk

Spirea is advancing an exciting and innovative pipeline of antibody drug conjugates that allow more drug payload to be specifically directed to the target of interest on the tumour cell. This results in an increase in therapeutic effect whilst substantially reducing debilitating side-effects. By delivering the right amount of the right drug to the right cells, Spirea’s proprietary technology will unlock a new generation of accessible, powerful and well-tolerated medicines for the treatment of a wide range of cancers. As well as developing its own drugs, Spirea will collaborate with partners on new programmes and to revive pre-existing preclinical and clinical-stage assets that have failed because of narrow therapeutic indexes.